Bearded dragons fitted with special backpacks showed animals that moved fast, died young
But Kristoffer Wild regularly found himself doing just that during his PhD at the Bowra Wildlife Sanctuary in Queensland.
"I became a tailor during my PhD," the University of Melbourne ecologist joked.
He'd measure the neck and chest of each lizard, before quickly setting up the sewing machine, cutting specially-designed material and stitching tiny, individually measured outfits.
Dr Wild then wrangled the backpacks — which weighed about as much as an AAA battery — onto the Australian central bearded dragons (Pogona vitticeps).
After the hour-long tailoring session, the lizards were set free sporting a new outfit stuffed with a GPS tracker, an accelerometer and a temperature tracker.
"[The backpack records] every single second of what the animal is doing, and senses if it's accelerating forward, backward, up and down," Dr Wild said.
The year-long study led to a wealth of data about how the lizards' temperature changed throughout the seasons, where they went and what they did.
But of all the data — which has today been published in the Journal of Animal Ecology — one thing stood out.
The speediest bearded dragons were the most likely to not survive to the end of the experiment.
"We usually think animals that are faster are more likely to evade predation," Dr Wild said.
Not only is this counterintuitive, but it goes against what prior research has found in the lab.
So what is going on?
Dr Wild and his team tracked 40 bearded dragons.
Because the team lived close by, they could also quickly check on any lizards when there was a problem, or when they were eaten by a predator.
"We could pinpoint the exact time of death and usually we could work out what caused it based off of how the carcass was left," Dr Wild said.
At the end of the study, they found most of the bearded dragons were eaten in the spring, and females were much more likely than males to be eaten.
"The males have to defend their territories, whereas the females have to hunker down and save all their energy for their eggs," he said.
But why the speediest dragons were the most likely to die was — at first — a mystery.
The Australian central bearded dragon is found throughout inland Australia, and at their largest can be up to 60 centimetres from tip to tail.
Its beefy nature might explain some of the results, Dr Wild suggested.
Because of their size, adult bearded dragons mostly use stealth, as opposed to speed to avoid predators.
"What does a bearded dragon do when you see it in the field? They use their patterns to blend into the background," he said.
This isn't the case for all lizards. Younger or smaller lizards instead try to use their speed to outrun a predator, but this makes them tasty targets.
"Whereas when they're larger, they're relying more on blending into their environment."
However, Martin Whiting, an animal behavioural researcher at Macquarie University who specialises in lizards, said although the paper was "valuable", larger sample sizes were needed to better understand survival in the wild.
"We do predict that animals that can sprint faster have a greater chance of surviving in the wild," Professor Whiting said.
"But this is still poorly understood, and this paper helps shake that paradigm a little."
Although past research has shown in lab conditions that lizards that are faster are more successful, Professor Whiting said there hasn't been enough research to confirm that is actually the case.
"What happens in nature is often not that black and white," he said.
"There might be systems where being the fastest sprinter is good, like if you're an antelope and about to be eaten by a cheetah. And then there are other systems where you might need to be more cryptic."
"You may not 'invest' in being a good sprinter."
From getting a waterproof, smooth material made from a local outdoor company, to sewing the vests himself, Dr Wild did what he could to ensure the trackers didn't harm the animals.
"We tracked the animals for a few days in a row just to make sure they were happy with the attachment, and they didn't get [stuck] on a fence or something.
"It worked pretty great."
But he also admits the vest isn't foolproof.
"You do have to tell yourself, 'Yes, we are manipulating the animals' behaviour because we're putting tracking gear on it,'" he said.
"But we're trying to minimise [the disruption] at all costs."
This includes how long it takes to put the outfit onto a bearded dragon.
"It's like putting a T-shirt on a toddler," he said.
According to Dr Wild, at his best he could put the vest on a wriggling lizard in just a few seconds.
And then, "once you get the T-shirt on, they're totally fine with it," he added.
According to Professor Whiting, the "gold standard" for putting a tracker on almost any animal is for the tracker to weigh about 5 per cent of the creature's body weight.
If the animal was human-sized, this could be anywhere in the region of 3 — 5 kilograms. Plenty of weight for a small tracker.
But the smaller the animal, the harder it is to fit in the battery, sensors and anything else you might need without going over 5 per cent.
An average bearded dragon female might be just 250 grams or so, meaning the whole kit needs to weigh under 12.5g.
Smaller lizards are even harder to attach.
"They are not that many studies where people attach this sort of technology to the animal and get this kind of data," Professor Whiting said.
"It's true the technology is getting better. We're getting smaller batteries for example, but once you get a smaller battery, then it's going to run out faster as well."
Dr Wild is looking to use this technology again in future research, and is optimistic about it being used on smaller and smaller species.
"Five years ago, somebody would tell you you're absolutely crazy if you were going to put [a GPS tracker and accelerometer kit] on something smaller than a bearded dragon," he said.
"But I was talking to somebody the other day, and they're putting accelerometers on little hatchling turtles to see how much movement they use when they're when they're hatching out of the nest."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
4 hours ago
- News.com.au
Hope grows as cannabis contender enters the Rett syndrome fight
Rett syndrome is rare but relentless Neuren struck biotech gold with Daybue Neurotech brings cannabis to the fight Rett syndrome is the kind of diagnosis that hits hard and lingers long. It affects around one in 10,000 girls, and typically appears after what seems like a normal start to life. Then comes the regression - loss of speech, hand skills, mobility - followed by the onset of seizures, bone fragility, gut issues, scoliosis and, often, a haunting silence that replaces early babble. It's caused by mutations in the MECP2 gene, which plays a crucial role in brain development. While it's classed as rare, the ripple effects through families are enormous. Sleep disturbances are common. Breathing irregularities, like breath-holding spells, can leave caregivers powerless. And while most girls survive into adulthood, it's with round-the-clock support and complex medical needs. AussieRett and InterRett studies Professor Helen Leonard, principal research fellow at the Kids Research Institute, has spent decades studying the condition. Leonard's long-running AussieRett and InterRett studies have helped establish how Rett symptoms evolve over time, and her team has also created global care guidelines for things like nutrition, scoliosis and bone health. 'Rett syndrome is an unusual condition in that it mainly affects girls who, following a period of apparent normal development, gradually show signs of regression," she told Stockhead. "Between the ages of 6 and 18 months they lose skills, particularly in relation to hand function and communication. 'As well as loss of hand function, these individuals develop unusual patterns of hand movements, such as hand-wringing or clapping known as stereotypies." Neuren's moonshot moment Until recently, there was no approved treatment for Rett, only a patchwork of management strategies and hope. That changed when ASX-listed Neuren Pharmaceuticals (ASX:NEU) struck gold with its drug trofinetide, now marketed as DAYBUE in the US. Approved by the FDA in March 2023, DAYBUE became the first and only drug for Rett syndrome, unlocking a commercial windfall for Neuren. Since 2019, Neuren's stock has surged over 1,200%, and the company now commands a $2 billion market cap. Thanks to a savvy licensing deal with Acadia Pharmaceuticals, Neuren pockets royalties and milestone payments with no royalty outgoings - every dollar drops to the bottom line. 'The FDA approval of trofinetide for Rett syndrome is very exciting, and represents the first ever treatment for the disorder,' said Leonard. For investors, it was a reminder that rare paediatric disorders, long overlooked, are now a serious biotech frontier. And that's where Neurotech (ASX:NTI) enters the frame, with a somewhat different approach. Cannabis steps into the ring Neurotech's lead therapy, NTI164, is a full-spectrum cannabis extract containing a cocktail of cannabinoids like CBDA, CBC and CBN. But it only contains 0.08% THC, meaning it's non-intoxicating and suitable for children. The company recently published results from its Phase I/II study in the Journal of Paediatrics and Child Health. This report shows the therapy was well tolerated and offered signs of clinical improvement across neurological, behavioural and functional domains. The drug's unique formulation is designed to reduce neuroinflammation, support synaptic function and modulate glial cells - factors believed to play a key role in Rett's progression. NTI164 is gaining traction internationally. It's already secured Orphan Drug Designation (ODD) in the US and European Union. This unlocks a range of incentives, including market exclusivity, reduced regulatory fees and access to research funding. It's the kind of support that can help fast-track rare-disease drugs through the system. Meanwhile, data from the same study was presented by lead investigator Professor Carolyn Ellaway at the World Rett Syndrome Congress. That put NTI164 front and centre in a growing global conversation about next-gen Rett treatments. Caution, hope and next steps Research into cannabis for Rett is still early, and Leonard urges caution when interpreting results from small, open-label trials. 'I think that we need a larger national double-blind placebo-controlled study before making any judgement,' she said. 'I would hope that this would use an alternative outcome measure to the RSBQ.' Her research has shown that Rett's behavioural symptoms - like those measured by the RSBQ - tend to decrease with age; unlike its clinical severity, which often worsens. That disconnect, she believes, can muddy trial results, and partially explains why she urges a broader toolkit for measuring impact in future studies. Still, she acknowledged that apart from the Rett Syndrome Symptom Severity (RTT-SIS) scale, some of the other measures used in the NTI164 study 'were showing positive changes'. She's not easily swayed by early signals but she recognises momentum when it's building. And regulators seem to agree. A closer look under NTI's hood From a clinical standpoint, NTI164 is ticking key boxes. Its pharmacokinetic (PK) data shows rapid absorption, minimal THC exposure and consistent dosing with no cannabinoid build-up - making it suitable for chronic paediatric use. NTI164 has also shown promising results in other paediatric neurological conditions like autism and PANDAS/PANS, potentially supporting its use in Rett by building a broader safety and efficacy profile. Perhaps most notably, its primary cannabinoid, CBDA, doesn't just convert into CBD like many assume. It appears to act directly on the brain, interacting with receptors linked to mood and inflammation. That matters because Rett isn't just neurological, it's deeply inflammatory. 'The clear validation of systemic stability, safety and targeted therapeutic action highlights NTI164's potential as a disease-modifying therapy,' said Neurotech CEO, Dr Anthony Filippis. Whether that turns into a commercial home run is still to be seen, but NTI164 has already demonstrated solid safety and early signs of symptom relief. In Rett, that bar is high. So are expectations. And that's what makes Neurotech's path an interesting one to watch. At Stockhead we tell it like it is. While Neurotech is a Stockhead advertiser, it did not sponsor this article.

ABC News
4 hours ago
- ABC News
Australian scientists record accelerating glacier loss on sub-Antarctic Heard Island
Glaciers on the remote Australian territory of Heard Island have lost almost a quarter of their size in the past seven decades amid rising temperatures in the sub-Antarctic region, new research shows. The World Heritage-listed sub-Antarctic island, 4,100 kilometres south-west of Perth, is considered one of the most pristine places on the planet and a haven for wildlife. It's also home to the tallest mountain in Australia's external territories — a 2,745-metre-high active volcano called Big Ben, which is 517 metres taller than Mt Kosciuszko on the mainland. But scientists from Monash University's Securing Antarctica's Environmental Future (SAEF) research centre said glacier coverage on the island was undergoing accelerating decline. The research team used topographic maps and satellite imagery to identify changes to 29 glaciers on the island between 1947 and 2019. The study showed the loss of 64 square kilometres of glacier coverage over the 72-year period — a 22 per cent decline. The team said the rate of ice loss after 1988 was double that seen beforehand. The reduction in the island's glaciers occurred as temperatures in the area increased by 0.7 degrees Celcius. "While Heard Island is just about as remote as it's possible to be on Earth, it has still suffered profound consequences from climate warming, which is almost certainly due to rising greenhouse gas emissions in the 20th and 21st centuries," Dr Tielidze said. "The island's location in the Southern Ocean makes it a key part of the global climate system and an important indicator of the planet's health. The study has been published in the academic journal, The Chryosphere, ahead of a planned research voyage to Heard Island and nearby McDonald Island in late September. The RSV Nuyina will take almost two weeks to sail from Hobart to the remote islands, where science teams, including glaciologists, will conduct research for about 10 days. It will be the first Australian Antarctic Program voyage to the islands in almost 20 years, and will be followed up with a second voyage there in December. Professor Andrew Mackintosh, from Monash University, said the mission would allow researchers to better understand the impact of glacier retreat on the island's mountain biodiversity. "We'll explore two possible futures — one where strong action is taken to reduce greenhouse gas emissions, and another where little is done and emissions continue as usual," Professor Mackintosh said. "Although this mapping shows stark glacier retreat and further ice loss is unavoidable, whether we retain glaciers or lose most of them entirely is up to humans and the greenhouse gas emission pathway we follow.

Sydney Morning Herald
6 hours ago
- Sydney Morning Herald
Deanna tried IVF with the lot. None of the costly, unproven add-ons worked, so she went back to basics
Australia's health ministers last month ordered a rapid review of the nation's assisted reproductive sector following a series of bungles and scandals, to determine if greater regulation can increase the safety and transparency of fertility clinics. Victoria is leading the national review, and a Victorian government spokesperson confirmed IVF add-on services would be included in consideration of existing or potential new legislative framework. 'A dedicated team has been established to undertake the review and will report back within three months,' the spokesperson said. Australia has the fifth-highest rate of IVF, fuelled by the strength of the commercial fertility sector and Medicare rebates with broad eligibility criteria that mean patients can continue coming back for cycles regardless of their chances of success. Four out five women accessing IVF also use add-on services during their treatment, which can greatly add to their costs as well as the profits and marketability of the clinics, but which may not increase the chances of success. An analysis of the non-core services being offered to Australian fertility patients by University of Melbourne researchers, prepared for this masthead, highlights the high costs and lack of evidence supporting services commonly upsold to potentially emotionally vulnerable patients. It reveals 44 treatment types ranging from free to $5000, and taking in everything from vitamins to plasma being injected into ovaries, genetic testing of embryos, injecting a single sperm directly into an egg and endometrial scratching, have little to no influence on the chances of having a live birth, pregnancy or miscarriage. Loading The analysis follows the launch of the Evidence-based IVF website in April, which is led by the University of Melbourne's Dr Sarah Lensen as an effort to better inform people undergoing IVF of the unproven add-ons. 'There are research articles out there on these different add-ons but the quality, broadly speaking, is really poor. Different providers are willing to draw the line in different places in terms of how much evidence they think they need before they're willing to offer or recommend something,' Lensen said. 'Sometimes there's a cost for special IVF conception vitamins or whatever, but they're probably pretty low risk, and they're not as big of a deal. 'Down the other end of the spectrum, there's the super-expensive $1000 treatment options that also come with risks because they're playing with patients' immune systems or injecting things into their ovaries that we don't really know what's going to happen. 'A lot of the add-ons that get offered slip through the cracks in terms of the existing regulatory system.' In Deanna Carr's case, she underwent two normal but unsuccessful cycles of IVF before adding steroids, blood thinners, aspirin and clexane during two further cycles. Determined more had to be done, Carr followed advice from online fertility forums and moved to one of Australia's largest clinics to seek out a specialist known for pushing the envelope. 'There's lots of conversation about which specialists to see, because these specialists are willing to be a lot more experimental – and, when we say experimental, it is literally meaning experimental. 'They're willing to try more add-ons, regardless of how inclined the research is to say that it doesn't work.' Tests at that clinic found Carr had a partial DQ Alpha gene match which may make her body more likely to attack or reject an embryo, though research suggests treatment for it does not significantly improve IVF success rates. To address the issue, a team of specialists gave Carr lymphocyte membrane immunotherapy, in which up to eight vials of blood were taken from her husband so his white blood cells could be extracted and then injected into her arm to correct her immune system with material that is genetically matched to their embryo. 'It's like weird blood brother stuff, and quite expensive,' Carr said. She was given a toxic cocktail of drugs including naltrexone and tacrolimus, which are more commonly used to treat cancer, as well as an intralipid infusion to 'knock out' her immune system. Added together, this cycle cost more than $8000. 'It didn't work. It ended up the same way all our other cycles ended,' she said. Carr's specialists then offered to step up the add-on treatments even further. They proposed a $5000 EMMA and ALICE test which would have seen Carr undergo another full IVF cycle but, rather than try for a pregnancy, the doctors would take a biopsy of her uterus to see if bacteria were present that might be impacting her pregnancies. If it found abnormalities, Carr was then to be prescribed cefalexin – a common antibiotic used for infections and cheaply available on the Pharmaceutical Benefits Scheme. 'It's what the doctor would give you for a sore throat. Why would they make me pay five grand for it? Why not just give me the medication?' Rather than spending $12,000 for another add-on-laden IVF cycle, Carr consulted the Evidence-based IVF site and realised there was little science to support the proposed treatment, then switched clinics to undergo a traditional – and successful – cycle. 'You get persuaded to add on because you obviously want it to work, and you're already spending so much, so this can financially tip you over the edge,' she said. 'A lot of these IVF companies know that. It does feel really unethical [because] a lot of the time people aren't being provided with proper information around the add-ons that are being suggested and the efficacy around them. And people are really desperate, so they'll just keep saying yes to things.' A Macquarie University professor of bioethics in the discipline of philosophy, Wendy Lipworth, last year published a study based on interviews with 31 doctors working in assisted-reproductive technology to see what their 'moral justification' for using add-ons was. The specialists' responses revealed evidence and innovation was not the driving consideration in many instances, and that regulatory reforms to only allow the use of unproven treatments in the context of formal scientific evaluation might be required. Lipworth said add-ons were often marketed as a point of difference between clinics, which may undermine individual doctors' ability not to offer them for patients. As a result, she believes any new regulation would need to focus on the clinics and what they are offering, rather than individual doctors wanting the best for their patients. 'Generally, there should be some expectation that they might at least be beneficial, even if there's no good evidence for it. That's a real balancing act,' Lipworth said. 'In fertility, the balance is going a little too far in the direction of too many things being offered without enough evidence. 'There might be room for some more regulation of how the products are advertised, how patients come to know about them, what they charge for them and so on. But the very act of using them is not in and of itself in any way unethical. 'What really matters is that people know that they're getting treatment for which there is not good evidence, and that they are able to make informed decisions about whether or not to use them. Loading 'That doesn't mean that anything goes and that patients should necessarily be able to walk into a doctor's surgery and say, 'my friend saw this on Facebook', or 'my friend used this and she got pregnant, therefore I want you to offer it to me'. 'There is still a duty of care to offer things that you, at the very, very least, are absolutely certain won't do harm.' Add-ons are not the only factor separating clinics, or the fees they charge. Lensen said premium clinics typically provide continuity of care so patients always get to see the same specialist and nurse, as well as improved customer service, which may not be provided at low-cost or public clinics. And, in many cases, the proliferation of add-on services is often more patient-driven than due to marketing by doctors or their clinics – which is why Lensen believes reforms are even more important, so regulators can step in when doctors fail to uphold their responsibility to dissuade patients from treatments that may not be in their best interests. 'The evidence is not that strong, but the patients are asking for it, or the clinic down the road is offering it, and so they end up using it too. But then when the research community does come out with robust evidence later, I think they do act,' she said. 'So it would be nice if we said from 'now on, no more offering a high dose of corticosteroids to patients. If you want to do that, they can take part in a placebo controlled trial'. 'A lot of the time, though, regulations are not aligned with the commercial interests of whoever they're trying to regulate – that's the whole reason we need them.'